Proove Biosciences Appoints Eric Fung, M.D. Ph.D., as Chief Scientific Officer
Irvine, CA (PRWEB) November 17, 2015 -- Proove Biosciences, a commercial and research leader in Personalized Medicine, is excited to announce the appointment of Dr. Eric Fung, M.D., Ph.D. as Chief Scientific Officer of the Company, effective August of 2015. Dr. Fung will head the expansion of the Research and Development team and will manage all applied research efforts and scientific product development.
“I am delighted to announce and welcome Dr. Eric Fung in his role as Chief Scientific Officer,” commented Brian Meshkin, founder and CEO of Proove Biosciences. “We’re excited to work together to develop new products to help improve patient care and physician decision-making. His expertise and success in prior companies, both private and public, leads me to believe that he is the right choice for the position. Dr. Fung has already become an integral part of the Company and I have no doubt that he will serve his role well.”
Dr. Eric Fung has developed and commercialized diagnostic tests throughout his professional career. At Ciphergen (now Vermillion), he developed and obtained FDA clearance for OVA1, a test for ovarian tumor triage and the first protein-based multivariate index test to be cleared by the FDA. He also worked on the ATHENA clinical trial at Roche, which was the pivotal clinical trial used to obtain FDA approval for their HPV cervical cancer screening test. Most recently, Eric was Vice President, Research and Development for Clinical Applications at Affymetrix, where he obtained FDA clearance for CytoScan Dx, the first and currently only FDA-cleared whole genome chromosomal microarray. In addition, Eric developed and launched several other molecular pathology products as well as developed and executed the reimbursement strategy. Eric obtained his MD, PhD at the Johns Hopkins University School of Medicine, with his PhD in neuroscience, followed by an anatomic pathology internship and cell biology post-doctoral fellowship at Stanford University.
“I am excited to join the Proove team, which is passionately devoted to personalizing medicine by applying advanced bio-informatic solutions to developing novel solutions in critical clinical areas such as pain management, treatment and prevention of addiction, and therapeutic drug selection, dosing, and toxicology,” said Dr. Eric Fung. “I am looking forward to developing new platforms on which genetic and phenotypic information can be combined to create and implement novel diagnostic tools to help physicians and their patients.”
About Proove Biosciences
Our Mission is to Change the Future of Medicine. Proove is the proof to improve healthcare decisions. We seek to realize a future when clinicians look back and wonder how they could’ve ever prescribed medications without knowing how a patient would respond. With offices in Southern California and the Baltimore-Washington metropolitan area, the Company is the research leader investigating and publishing data on the genetics of personalized pain medicine with clinical research sites across the United States. Physicians use Proove Biosciences testing to improve outcomes – both safety and efficacy of medical treatment. From a simple cheek swab collected in the office, Proove performs proprietary genetic tests in its CLIA-certified laboratory to identify patients at risk for misuse of prescription pain medications and evaluate their metabolism of medications. For more information, please visit http://www.proovebio.com or call toll free 855-PROOVE-BIO (855-776-6832).
Hana Greenwood, Proove Biosciences, http://www.proovebio.com, +1 855-776-6832 Ext: 1522, [email protected]
Share this article